Hello, and welcome to IBA's half-year 2023 results conference call. All participants are currently in a listen-only mode. A question and answer session will follow the formal presentation. I will now hand over to Olivier Legrain, Chief Executive Officer of IBA. Thank you, Olivier, and good afternoon, and thank you for joining us today on this results call. I'm joined today by Soumya Chandramouli, our CFO. Before we start, I would like to draw your attention to the company disclaimer on forward-looking statement. Here is an overview of today's call. I will start with IBA performance and progress of the first half with a detailed look at the different business units. Soumya will then provide commentary on the financials before I talk through the outlook and then open the line for questions. I'll kick off with an overview of the first half performance. Here is a snapshot of the key financials. There's been a modest uptick in revenues in the period related to solid other accelerators, backlog conversion, strong dosimetry sales, and service revenue growth. However, there is a significant phasing of our proton therapy revenue recognition to the second half of 2023. Alongside investment made at the group level to future-proof the business, as well as prepare for the acceleration in the second half, proton therapy revenue recognition has impacted our REBIT. The rate of growth has been relatively slower during this first half period. However, we are expecting a significant ramp-up in the second half. REBIT was impacted by three factors: reinvesting for growth for the expected increase in the activity in the second half, timing of several projects that are planned to start in H2, and some unrelated customer-specific installation delays. You'll recognize this slide from our full year results. We remain committed to the key objectives laid out for each business unit. This is underpinned by a group-wide focus on digital developments as well as sustainability initiatives. Moving on to strategic progress on these objectives across the business units during the period, Dosimetry has had an excellent first half, with excellent growth in order intake, alongside product launches and upgrades. We'll discuss the impact of Modus and ScandiDos in more details later. Within proton therapy, we have seen an encouraging increase in service revenues. Our commitment to proton therapy innovation continues, and we were pleased to start a new research partnership with ParTICle earlier in the year. Moving to Radiopharma, we are pleased to have launched AKURACY, a cardiac imaging solution, and reach another milestone with our joint venture, PanTera. Industrial has seen very strong revenue growth. Elsewhere, it has been pleasing to see the potential for our technology in a growing range of applications, including food irradiation. More than 100 participants are expected to join our food irradiation symposium in September. Finally, at the group level, IBA has been investing into digitalization, which includes, among others, the development of a business-wide predictive maintenance platform and the launch of a customer-dedicated web portal for industrial business. During the period, we continued to make good progress on our four sustainability-related streams, and I'd like to highlight the B Corp recertification now in progress with a target for 2024, the risk-mapping exercise started with EcoVadis on our supply chain, and the various ESG initiatives being taken at employee level. Let's take a look at the key figures for the first half. As noted, first half performance was strongly impacted by a number of proton therapy factors, including timing of backlog conversion and investment in the business that I will comment more in details in the later. Elsewhere, other accelerator and dosimetry performed very well, with sales growth of 30% and 23%, respectively, and a strong profitability. REBIT margin was affected by the combination of the low proton therapy backlog conversion already outlined, alongside higher investment in sales and marketing and R&D, in anticipation of ramp-up in the second half of the year and beyond. Net cash sits at a healthy EUR 61.7 million. As part of a scheduled renegotiation, an unused EUR 37 million syndicated credit facility was refinanced in August, increasing to EUR 40 million. A total unused credit line now stand at EUR 44 million. Let's move on now to a deeper dive on the proton therapy business unit. Taking a look at the proton therapy market more broadly, so far this year, IBA remains the clear market leader, with 60% market share in the proton therapy room sold. IBA has also maintained its leading position in number of rooms in operating and total market share. Proton therapy order intake for the first half was EUR 59 million, with 3 rooms sold globally. Revenue decreased by 6% in the period, while we expect a second half weighted to year. As already been the case in the past few years, this effect was even more marked in 2023 due to 3 main factors: an anticipated second half phasing of 5 major projects, with no major start, shipment, or completion of project in H1. An unexpected shift of 3 projects from H1 into H2 for unrelated reasons, and order intake, which came late at the end of the first half. In addition, there were inflation-related costs that were adjusted on project costs to completion. With a record backlog of more than EUR 700 million, comprising 35 ongoing projects, there is continuing focus to accelerate conversion to revenue in H2 and beyond. As we have seen across the group, service, on the other hand, continue to grow in proton therapy. At 10%, a backlog of EUR 670 million remains. Now, moving to other accelerator performance, interest in IBA's proton machine remains high, particularly in sterilization settings, where it is meeting a significant gap in the market. Despite a slower intake, order intake, impacted by macroeconomic factors, revenue climbed over 72%. This was thanks to high order intake during 2022, and the now increased footprint, meaning that service revenue is increasing. Demand for IBA's radiopharma solutions remains strong, and the business remains the market leader for accelerator of radioisotope production. AKURACY and INTEGR ITY solution for cardiac PET imaging was launched back in May. Elsewhere, we were pleased to successfully install a Cyclone 30 XP in Jülich, Germany, for the production of the radioisotope astatine-211. We have continued to make progress with our joint venture, PanTera, focused on increasing the global supply of actinium-225. In the near term, this is enabling production for use in ongoing clinical trials. Longer term, it is hoped that the partnership will allow a large scale. I forgot to speak about the signed agreement with TerraPower, which will, near term, enable us to produce doses for ongoing clinical trials. But longer term, this partnership, it is hoped, it will allow large-scale supply of the isotope. First period, we made a EUR 20.4 million contribution to the capital of PanTera, mostly in kind, with another EUR 20.4 million equity, was also brought in by our partner in the joint venture, the SCK CEN. Post period, we were also pleased to sell three further machine, including Cyclone KIUBE, cyclotron in China. Alongside the cyclotron, a strategic collaboration has been signed with the buyer for the production of radioisotope for cancer diagnosis. Taking a closer look at the financials, I'm pleased to report a solid order intake of EUR 29 million across eight system. While this was weaker than last year for the same period, we have already started to catch up, as mentioned earlier, with 3 additional machines sold post period. Equipment revenues increased by more than 20%, to EUR 4.3 million, due to good backlog conversion. 10 installations started in the first half, with 21 installation expected to initiate by the full year. The service part of the business performed extremely well, growing by almost 50% due to an increase in install base, several upgrades to existing machine, and a strong replacement parts business. On the other accelerator slide, EBIT loss of EUR 0.5 million includes impact from inflation, particularly in Belgium. Let's move on to Dosimetry. It's been a strong first half for Dosimetry, with order intake reaching another record of EUR 37 million. The 20% uptick is linked to demand for conventional radiation therapy and proton therapy quality assurance solutions, as well as 2022 Modus acquisition. Sales are up 23% to EUR 33 million, with around EUR 1.5 million attributable to Modus. Backlog also increased to a record high of EUR 35.6 million, growing 47% from the end of 2022. This excellent level of sales contributed to Dosimetry EBIT, increasing more than 200% to EUR 3.2 million. On the product side, DOSE-X, a next generation electrometer, was launched in April. At ESTRO, we were pleased to demonstrate upgrade patient QA software, myQA iON 2.0, as well as launching a radiation oncology risk management software called myQA PROactive. During the period, we were pleased to build on the strategic alliance first agreed with ScandiDos in last year in August 2022, signing a distribution agreement enabling users to buy the combined my QA iON and Delta4 Phantom+ directly from IBA. I now will hand over to Soumya to take you through the financial statements. Thank you, Olivier. Good afternoon, all. First, looking at the P&L, you will note that group sales grew by 6%. This is largely attributable to other accelerators, backlog conversion, excellent Dosimetry sales, and services growth, but was impacted by PT backlog conversion and the comparator with 2022, which included certain Rutherford-related incomes. While G&A expenses were strongly controlled and even beat inflation, rising by just around 1%, there was an increase in sales in marketing and R&D expenses with inflation, higher level of travel and marketing, expenditure, as we prepare for future growth and product development. I'd also like to highlight the impact of currency fluctuations in the period, which had an impact on our financial result, as well as the tax line that increased as we expand into new geographies, especially in Asia. The above impacts contributed to a net loss of EUR 27 million for the period. Now moving on to cash flow. Operating cash flow of EUR -43.7 million was impacted by a large inventory increase and an uptick in down payments to suppliers, as the company geared up to deliver projects in H2 and beyond, in particular, in the proton therapy and industrial businesses. As outlined previously, H1 has seen significant levels of investment across the business, including in digital costs. Cash flow here was also impacted by medical device regulation costs and by a minor acquisition in the radiopharmaceutical business. Finally, on the balance sheet, I won't go into much detail, but I would like to highlight the solid balance sheet with a high level of inventory in preparation of backlog conversion and a net cash position of EUR 61.7 million. I now hand back to Olivier to take us to the outlook. Thank you, Soumya, and looking ahead, we are confident that the second half will see strong performance, not just in proton therapy, but also in all our other businesses, underpinned by the quality of our backlog and the ongoing preparation by the full organization at IBA to convert into revenues. We are reiterating our midterm guidance today, as laid out at the full year, aiming to deliver 10% REBIT on sales, heavily weighted to after 2024. I would now like to open the floor for questions. Yes? Yeah. Laura Roba from the Gulf has a question. You're live. Thank you. Thank you for taking my question. Could you quantify the impact of the postponement of the three PT system that were supposed to to be installed in H1 on REBITs? Well, we don't give specific numbers- Okay. but we can certainly say several million EUR. It's calculatable in millions. Well, what I can say is that basically every project, if you look at one Proteus, one project, which is in the region of revenues of around 20 million EUR or so, and delivers over around 3 years, well, there's a big bump usually where around 30% of costs are recognized at shipment, and that leads to revenue, related revenue recognized also at the point of shipment. And since those are shifted to H2, you can basically more or less calculate what the impact of the shift of 3 projects into H2 would be. Great. Okay, thanks. And yeah, more question on H2. How confident are you that these eight systems will be installed? Pretty confident, otherwise, we wouldn't have mentioned it in the results call. I don't know if you have any comments. Well, I think what you can say is that for 6 out of 8, it's fully under our control, because we speak about what we call the outbounding phase. Outbounding phase means we are putting all the equipment into boxes to be shipped, and this is fully under our control. For 2 others, it depends on readiness of the buildings of the customer. So this one are, let's say a bit less under our control. Mm-hmm. but we're pretty confident that it will happen. We have a question from David Vagman online. David? Yes, hello. Good afternoon, everyone. Sorry, I want to unmute myself, so thanks for taking my question. Maybe first to come back on the 2023, could you give us a rough idea of where, let's say, the very rough idea, let's say, of where the 2023 rebids could land? Maybe give us a range. Should we expect the rebid to turn positive for H2, so basically, and the full year rebid to maybe turn positive? That's my first question. And second question, given that all the PT projects are landing in H2, what kind, what level of PT equipment sales growth rebound should we expect? Again, a range could maybe be helpful. The last question on the other accelerators. You had a very good, very high level of growth, sales growth, in H1. Could you explain us why we didn't see more operating leverage, so in terms of profitability, and how should we think about the profitability or the other accelerator, so for the full year, at the full year level, the margin side? Thank you. Maybe I'll start by the last question, and I cannot be specific because we don't give short-term guidance. But what you will see in other accelerator is a bit similar to what we see in photon therapy. So yes, we have seen growth in the first half, but we expect even more growth in the second half. And you have a bit of the same effect. Yes, we have inflation, but we have also prepared for that growth, and therefore we have invested into these two businesses as well. Same kind of narrative than on proton therapy. So we have an increase of sales and marketing expenses, and research and development, which basically has compensated for the operational leverage. But once again, we're doing it because we expect an acceleration of growth in other accelerator as well. For the rest, I think, you know, I think it's going to be a short answer because we don't want to give specific guidance on short-term specific guidance, so it's difficult to answer your question, even with a range. Once again, and I think we have already alluded to that, we can expect the second half very different than the first one. Okay, thanks, Olivier and Soumya. And maybe a very quick follow-up, more on the general climate, though we saw, even if the book-to-bill remain above 1 for Other Ac celerators, we saw quite a drop year-over-year, I would say. What can you tell us about, in general, on the client side, their let's say, their willingness to invest? And so we see some hospitals, clients struggling for other type of suppliers also, then on the clinics, maybe the industrial client. Do you see them postponing project, canceling project due to inflation, due to higher financing cost or macro uncertainties? Thanks. Yeah, again, I mean, in radiopharma solution, we don't see that. We have the same momentum around the world. We're pretty spread around the world as well, so we're not very market dependent. On industrial, we witness a bit of a pause in terms of order intake, even though we are confident it will resume. There's a bit of a bullwhip effect on the medical device of the consumable or the, what do we call it? The small medical device- Disposable. Disposable medical device, due to post-COVID bullwhip effect. So they have built up significant inventory, so they are a bit less in a hurry to build up sterilization capacity. And indeed, so I think from what we see in the market, we expect it to resume in the second half, but definitely we've been impacted in the first half by a bit of a pause on the sterilization market when it comes to order intake. Maybe just to add on that, if you remember, the growth in the industrial business was coming from several angles. It was coming, of course, from a growth overall of the overall sterilization volumes, but also from a conversion of existing technology to X-ray and E-beam. So I think indeed, as Olivier said, that on the volume side, it's probably getting... It's got slightly slower because of the effects he just explained. On the conversion side, we expect that that conversion will continue as an industry trend. Mm. As mentioned earlier on, for example, we are also seeing encouraging discussions on food irradiation. So we're also seeing that potentially there will be other avenues of increased volume than the medical one itself. Having said that, there is no change whatsoever in the plan to convert a big part of their capacity to X-ray, yeah? Yeah. Or E-beam X-ray. So it's more of a pause than questioning the idea of doing it, but the commitment remains extremely strong with the big guys. Okay, that's, that's clear. Thanks. Thanks, both. Question? Nikki has a question for you. Yes. My first question would be on the other accelerators. I recall that in the past, you gave, like, a complete breakdown of the backlog also in terms of other accelerators. And I think at the year-end 2022, that was still high, the equipment. How I estimate it would be EUR 150 million-EUR 200 million, maybe. So I'm a bit surprised because you mentioned, okay, we have a good increase for the other accelerators, yet it looks like, given the usual timeframe, it's a bit below the normal budget. Is there... Yeah. Are there some delays on that front? No, no, I think it's all to build up of inventory to be able to deliver. You are really... You, you are right, so we see a much stronger H2 in Other Accelerators as well. So we've seen, we've seen increase in H1, but we'll see a stronger increase in H2. If your point was, is the backlog not converting fast enough, is there some problem there? Not really, because if you look at 2022, a lot of the backlog that we had at year end came in the last months of 2022. And so there's a 12-18-month gap between the time when we get it into order intake and it really delivers. And so there, it's just normal. We'll see that converting into revenue faster in H2 and beyond, of course. Okay. But yeah, it should be- We should see a much bigger increase in revenues there also, indeed. Okay. Because indeed, you mentioned that at some point, that industrial has improved, increased by 72%. Well, I think it will be stronger, even stronger- Yes. Even stronger. Okay. And can you... Because I think the operational cost, it was, yeah, well flagged already last year that you were going to invest. How should we look? And maybe first on the operational cost, going into the second half, will that come down a bit? Will it remain stable? Will it go up on an absolute basis? And then secondly, maybe follow up in terms of the gross margin mix, which was, you know, quite low. Can you give a bit dynamics of, or the rationale? Is it because, yeah, you have the highest gross margin with the shipment, or, if you can give some color on that. First of all, on the OpEx, you can expect a stabilization of it. So no decrease, no increase, but we have reached a bit the altitude, paying altitude, let's say. So we'll see what inflation will give us for next year. We're pretty confident there as well. I think the first number will be a bit back to normal, more of like inflation plus, but no major increase. When it comes to the mix, you're right. I think we, you know, with a low level in proton therapy, we have to a certain extent, let's say, absorption of our overhead cost. So with the acceleration of the backlog conversion, we will see an improvement of the gross margin. Not only due to the mix, but due to the acceleration of the backlog conversion. Was there for the other accelerators, was there also a gross margin contraction there? 'Cause like David mentioned, I mean, you grew more than 20%-30%, and it's your profit margins remained stable on an absolute base. Is it also because you had some gross margin contraction on that end, or? No, but there's investment going on also over there. I mean, we have seen and heard during the call that we mentioned that we're investing quite heavily in digitization of that business also. So that has an impact, and of course, we're also ramping up in industrial also, because to meet the order intake that has come in over the last 18 months, we also had to up our procurement on that side. So that's also had an impact, but again, as we expect that the revenues will increase over H2, and also, yes, to some extent, the margin percentage will increase, because many of the contracts that we sold later on, later in 2022 had better margins than the previously sold ones. I think we'll also see an improvement over there. Okay. It's clear. Thank you. Go ahead, Laura. Yeah, still one question from my side. So you mentioned an uptick and yeah, an anticipated uptick in order intake in PT. Could you provide a bit more color on that? How does the pipeline look like, like? I think there's quite a good momentum in the U.S. and China, I believe. So yeah, U.S. and China. Some other parts of Asia also. Yes. Let's say US and Asia, yeah. Okay, thank you. So, yes, we have good momentum. David has a question online. Go ahead, David. Yes, thank you. One more question on the gross margin and inflation. So can you break down, let's say, the drop of the gross margin in H1 versus last year? So we had, of course, the, I think, the EUR 7 million related to PPI. And then you don't play in, let's say, so to speak, in inflation, let's say, of raw mat and I don't know, maybe staff as well, the technical staff, and you're rather referring to the, let's say, the scale impact, so of having less revenues than anticipated. So can you break down a bit between, let's say, a third of the drop in margin is inflation, two-thirds is just scale, volume? We think about it this way? Well, I think the major portion, more than 50%, is really down to a non-absorption of overheads. Mm. Because you, if you read through the press release, you may have seen that the actual cost of our projects have really not increased a lot. On the overall cost basis, which is basically hundreds of millions EUR, with a 700 million EUR revenue backlog, you can make a rough estimate of what that means in terms of cost. We've only seen around 1.2% cost increase, so that's not a lot. But what you do have is that when you have a cost increase, it hits your P&L directly, because you also have to readjust your past margin to the new margin. If... I'm sorry, that's a bit technical, but basically, it hits directly in the period, even though over the duration of the project, it's a small cost increase. Mm-hmm. So that's that has a double effect on the margin for the period. Now, if I look at the overall gross margin, I think more than 50% is indeed related to non-absorption of overheads. There is some level of product mix. We do have some projects, which have been sold at lower margins, and we had some level of delivery of production, I would say, to those projects, rather than- Mm ... to ones at a higher margins that are coming, in the future. So I think what we expect is that, indeed, while it won't, there won't be a crazy improvement of the gross margin, I think there will be some level of improvement of gross margin indeed, as we start to absorb more. Okay, not crazy, you mean improvement in H2, that, that's what you mean? Yes, yes, yes. Sure. Okay, okay. And maybe to finish on the inflation and gross margin, when should we see really, like, an improvement or, let's say, you not being impacted anymore by inflation at the gross margin level, i.e., what I mean is, when in your orders you would have, let's say, correctly priced the raw material inflation and, I don't know, technician inflation, et cetera, or protected yourself maybe also contractually, is that more something for 2024 or 2025, when you would have processed, let's say, enough of your historic backlog? Yeah, I think to some extent, we'd already mentioned it, that after and during the COVID crisis, we started to adapt our contracts to make sure that we're able to pass on a portion of the cost increases to our customers, and that certainly happened in all the contracts that have been signed since then. We continue to have some contracts that were signed before that period, and indeed, some of those, it's more of a negotiation with our customers. We've been able to transfer costs to them in many cases, in some cases not. But indeed, I do expect that that will, that effect will be smoothed out over the coming months as we have more and more of the projects where we do not have those costs, those extra costs attributable to I- ... Okay, so let's say that historic over rank is more something to be solved in the next months, rather than, let's say, in the next 18 months? Yeah, well, I mean, you know, our backlog, as you, as you know, for most projects, converts over 3-4 years. Some projects it can be longer because you have some projects which get stuck on there, and which, it takes much longer to convert. But indeed, it's probably something which is, which is a question of, I don't know, the next couple of semesters, I would say. Okay, clear. Thanks. I just have a small question on the number of proton therapy systems which are generating the services. I noticed that there was a bit of a drop in there, from 41 to 37, if I'm not mistaken. Just trying to understand why, nevertheless, your services revenues are up? Yep. So that was, that's related to Rutherford. So we had to remove the Rutherford contracts from our services because those stopped. But then we've been renegotiating new contracts in the meantime, and of course, we had new contracts that came into our service also during the period, and so one compensates the other, basically. Okay. Then on the cash flow going forward, you have, of course, the working, like the investments in the inventory to ramp things up. I think that's for... Is that for everything in the second half, or also a part related to everything that needs to come with the- yeah, with the project in Spain? How should we see? 'Cause, if it's for the Spain project, I don't expect it to see it normalized, like, instantly in the second half. So how should I look at it for the second half, and when should we see, like, a full normalization? So indeed, the inventory buildup that we have right now is not only for proton, by the way, it's also for the industrial and even for the radiopharma business, because last year, that radiopharma business also had a very high level of order intake. Of course, the rotation cycles for radiopharma and industrial are smaller. So for radiopharma, they're really short. It's in between, I would say on average, six months or so. For industrial, it's still between 12 and 18 months, but still much shorter. So we are already procuring also for beyond 2023 H2. I would say that we will probably see some level of drop of the inventory over H2, but it won't come back to what it was end of 2022, because we continue to procure for 2023. Just as you said, indeed, the 10 deals in Spain are also going to deliver some level of revenue in H2. Of course, they will not be shipped, but there will be some level of recognition as we have built up on those also. So, I explain it. If I understand this correctly, for the proton therapy delays, what you mentioned in the press release was that there were 5 systems planned for the second half. These remain, and originally there were 3 planned for the first half, and these 3 got postponed. That's correct, then? Right. Correct. Yeah. And in terms of capacity, that should not be... No? No, because usually we have dedicated teams who make sure that the inventory is shipped out, and of course, our installation is dedicated teams. Okay. Thanks. I have a question from Simon. Go ahead, Simon. Thank you. You're still on mute. Yes, I was. Sorry, sorry about that. So a very quick one, still on proton therapy. So the first half, there was not a single installation payment coming in. Second half, let's assume that we'll have 8. Every installation, shipment, or whatever, brings about EUR 3 million on average or even more, as a revenue for you. So is it fair to say 8 times 3, that's gonna be the difference versus the first half contribution for proton therapy? That's an assumption. Well, I mean, it's just based on everything that you're saying. Yeah. So that basically means that your result should be EUR 24 million in the second half for PT, for PT, indeed. Are you speaking in revenue, Simon? No, just the delta, because you get the money in, which is different from what happened in the first half. No, so it's not related to cash. You know, as you remember, our cash is completely dissociated from our revenue recognition, because cash is based on milestones, and revenue recognition is based on cost recognition. But if you look at it from another angle, basically, indeed, I think we will see a very big ramp-up in revenue in H2, because every shipment, as I mentioned, has indeed a big chunk of revenue associated with it, which has not got any relationship with the cash, at least not direct, but indeed, does lead to a big level of revenue recognition as that cost is registered on that project. On the number itself, I'm not gonna say anything, but the eight projects are a mix of Proteus PLUS and Proteus ONE, and you need to remember that a Proteus PLUS contract, of course, is worth much more than a Proteus ONE. And so there could be a much bigger level of revenue recognition on those Proteus PLUS contracts. ... Okay, thank you. And then on the other accelerators, can you give a bit of a example on investment to future-proof? Because this been already a segment that's been doing very well for the last two years, I would say. And can you quantify how much that investment was? Because we- Oh, but- I think we read a little bit with the understanding that the margins in the other accelerators are significantly higher than in proton therapy. Mm-hmm. It's a fair assumption. I can give you the example, like, we are currently installing a number of machine in the US, for industrial. And historically, in the US, we have no field service engineer to maintain the machine in the US, and we're building a team to actually be in a position to maintain the machine as soon as they will be operational. And this has impacted our profitability in the first half, because when we hire someone, we have what we call an apply time, which is the billable, let's say, number of hours of a person, which is very low in the beginning, and it is increasing as they are trained and fully operational. And we speak, you know, certain number of people that we have onboarded, not only in the US, in Asia as well, and train, and that will continue to be trained in 2023, to be in a position to maintain the machine that will—when they will be up and running. So that's an example of investment we've made to build up the capacity. And if and when we sell more machines in the US, then we can count on them, so there as well, there's a potential operational leverage on something that has been an investment, a pure investment in the first half. Okay, but you cannot quantify that? No. I can, but I will not. Okay, um- But once again, I think we had a question earlier on, why don't we see the operational leverage on other accelerator? Well, this is a big part of the answer on why we don't see an operational leverage on the other accelerator, so you can actually do the calculation. Yeah, that's clear. Thank you. Do we have more question online? No, not for now. Okay, in this case, I will now close the call, and thank you all for joining. I think we look forward, as you look forward, to updating you on our future progress in the future. Thank you very much for joining, and speak to you soon. Thank you. Bye, everyone.